The 69 references in paper V. Kazantsev A., I. Guchev A., В. Казанцев А., И. Гучев А. (2014) “Антибактериальная терапия обострений нетяжелой хронической обструктивной болезни легких // Antibacterial treatment of moderate chronic obstructive pulmonary disease exacerbation” / spz:neicon:pulmonology:y:2014:i:4:p:105-111

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (Updated
(check this in PDF content)
2
14). Available at: http://www.goldcopd.org/uploads/users/ files/GOLD_Report_2014_Jun11.pdfGlobal Initiative for Chronic Obstructive Lung Disease, Inc; 2014. 2. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization, 2001. (Accessed 07, May, 2014, at http://www.who.int/drugresistance/WHO_ Global_Strategy_English.pdf?ua=1.).
(check this in PDF content)
3
Llor C., Moragas A., Hernandez S. et al.Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 716–723.
(check this in PDF content)
4
Vollenweider D.J., Jarrett H., Steurer'Stey C.A. et al. Antibiotics for exacerbations of chronic obstructive pulТаблица Уровень резистентности клинических штаммов S. pneumoniae к 14–15? и 16?членным макролидам в России (различия обусловлены преодолением 16?членным макролидом и линкосамидами эффлюксного М?фенотипа устойчивости), % Публикация14! и 15!членные Клиндамицин, макролидыджозамицин Регионы РФ, 2006–2009 [33]6,44,3 Москва, 2004–2007 [65]11,48,9 Москва, 2009–2013 [66]2620 Санкт!Петербург, 2010–2013 [67]31,214,8 monary disease. Cochrane Database System. Rev. (Online) 2012; 12: CD010257.
(check this in PDF content)
5
Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
6
Stockley R.A., O'Brien C., Pye A., Hill S.L.Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000; 117: 1638–1645.
(check this in PDF content)
7
Russo R.L., D'Aprile M.Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Pharmacother. 2001; 35: 576–581.
(check this in PDF content)
8
Allegra L., Blasi F., de Bernardi B. et al. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a revaluation of previously published data of a placebo-controlled randomized study. Pulm. Pharmacol. Ther. 2001; 14: 149–155.
(check this in PDF content)
9
O'Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease 2003. Can. Respir. J. 2003; 10 (Suppl. A): 11A–65A.
(check this in PDF content)
10
Ram F.S., Rodriguez'Roisin R., Granados'Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (Online) 2006; 2: CD004403.
(check this in PDF content)
11
The OMBIRT Consensus Panel. Outpatient Management of Bacterial Infections in the Lower Respiratory Tract (OMBIRT): Diagnosis, Evaluation, and Antibiotic Selection in the Primary Care Setting. Atlanta, Ga: American Hlth Consultants; 2001.
(check this in PDF content)
12
Wilkinson T.M., Donaldson G.C., Hurst J.R. et al.Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 1298–1303.
(check this in PDF content)
13
Cheng T., Gong Y., Guo Y. et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin. Respir. J. 2013; 7: 305–318.
(check this in PDF content)
14
Jong Y.P., Uil S.M., Grotjohan H.P. et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007; 132: 1741–1747.
(check this in PDF content)
15
Yamaya M., Yasuda H., Yoshida M. et al.Treatment and prevention of COPD exacerbation. Nippon Rinsho. 2007; 65: 734–739.
(check this in PDF content)
16
National Heart, Lung, and Blood Institute, World Health Organization. Workshop report: global strategy for the diagnosis, management, and prevention of COPD: updated 2007. Available from URL: http://www.goldcopd.org. Accessed November 29, 2009.
(check this in PDF content)
17
Niewoehner D.E.Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation. EvidenceBased Med. 2008; 13: 145.
(check this in PDF content)
18
Hopkinson N.S., Man W.D., Dayer M.J. et al.Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 137–142.
(check this in PDF content)
19
Lindenauer P.K., Pekow P., Gao S. et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann. Internal. Med. 2006; 144: 894–903.
(check this in PDF content)
20
Rizkallah J., Man S.F., Sin D.D.Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009; 135: 786–793.
(check this in PDF content)
21
Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355–2365.
(check this in PDF content)
22
Pela R., Marchesani F., Agostinelli C. et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch. Chest Dis. 1998; 53: 262–267.
(check this in PDF content)
23
Murphy T.F. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2009; 15: 138–142.
(check this in PDF content)
24
Miravitlles M., Espinosa C., Fernandez'Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999; 116: 40–46.
(check this in PDF content)
25
Ko W.C., Paterson D.L., Sagnimeni A.J. et al. Communityacquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg. Infec. Dis. 2002; 8: 160–166.
(check this in PDF content)
26
File T.M. Jr, Monte S.V., Schentag J.J. et al.A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics / pharmacodynamics of the antibiotic. Intern. J. Antimicrob. Agents. 2009; 33: 58–64.
(check this in PDF content)
27
Mannino D.M., Davis K.J., Kiri V.A. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir. Med. 2009; 103: 224–229.
(check this in PDF content)
28
Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases society of America / American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 (Suppl. 2): S27–S72.
(check this in PDF content)
29
Martinez F.J., Han M.K., Flaherty K., Curtis J.Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Exp. Rev. AntiInfect. Ther. 2006; 4: 101–124.
(check this in PDF content)
30
Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): E1–E59.
(check this in PDF content)
31
Russi E.W., Karrer W., Brutsche M. et al.Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration. 2013; 85: 160–174.
(check this in PDF content)
32
Georgopoulos A., Borek M., Ridl W.Randomized, doubleblind, double-dummy study comparing the efficacy and safety of amoxicillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 2001; 47: 67–76.
(check this in PDF content)
33
Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового исследования ПеГАС). Клиническая микробиология и антимикробная химиотерапия. 2010; 12 (4): 329–341. / Kozlov R.S., Sivaya O.V., Krechikova O.I., Ivanchik N.V.Streptococcus pneumoniae antibacterial resistance dynamics in Russia in 1999–2009 (results of PeGAS multicenter study). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2010; 12 (4): 329–341 (in Russian).
(check this in PDF content)
34
Сивая О.В., Козлов Р.С., Кречикова О.И. и др.Антибиотикорезистентность Haemophilus influenzae в России: результаты многоцентрового исследования ПеГАС. Клиническая микробиология и антимикробная химиотерапия 2014; 16 (1): 57–69. / Sivaya O.V., Kozlov R.S., Krechikova O.I. et al. Antibacterial resistance of Haemophilus influenzae in Russia: results of PeGAS multicenter study. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya 2014; 16 (1): 57–69 (in Russian). Казанцев В.А., Гучев И.А. Антибактериальная терапия обострений нетяжелой хронической обструктивной болезни легких
(check this in PDF content)
35
File T.M., Garau J., Jacobs M.R. et al.Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2 000 / 125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Intern. J. Antimicrob. Agents. 2005; 25: 110–119.
(check this in PDF content)
36
Piroth L., Martin L., Coulon A. et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob. Agents and Chemother. 1999; 43: 2484–2492.
(check this in PDF content)
37
Siquier B., Sanchez'Alvarez J., Garcia'Mendez E. et al.Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin / clavulanate (2 000 / 125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 2006; 57: 536–545.
(check this in PDF content)
38
Dagan R.Achieving bacterial eradication using pharmacokinetic / pharmacodynamic principles. Int. J. Infect. Dis. 2003; 7 (Suppl. 1): S21–S26.
(check this in PDF content)
39
Bradley J.S., Byington C.L., Shah S.S. et al.The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of america. Clin. Infect. Dis. 2011; 53: e25–e76.
(check this in PDF content)
40
Gupta K., Hooton T.M., Naber K.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011; 52: e103–e120.
(check this in PDF content)
41
Zambonino M.A., Corzo J.L., Munoz C. et al.Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatr. Allergy Immunol. 2014; 25: 80–87.
(check this in PDF content)
42
Gruchalla R.S., Pirmohamed M.Clinical practice. Antibiotic allergy. N. Engl. J. Med. 2006; 354: 601–609.
(check this in PDF content)
43
Khasawneh F.A., Slaton M.A., Katzen S.L. et al. The prevalence and reliability of self-reported penicillin allergy in a community hospital. Int. J. Gen. Med. 2013; 6: 905–909.
(check this in PDF content)
44
Bauernfeind A., Jungwirth R.Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection. 1991; 19: 353–362.
(check this in PDF content)
45
Auckenthaler R.Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J. Antimicrob. Chemother. 2002; 50 (Suppl.): 13–17.
(check this in PDF content)
46
Nix D.E., Symonds W.T., Hyatt J.M. et al.Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy. 1997; 17: 121–125.
(check this in PDF content)
47
Hausen T., Weidlich G., Schmitt J. Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany. Infection. 1995; 23 (Suppl. 2): S65–S69.
(check this in PDF content)
48
Lorenz J., Steinfeld P., Drath L. et al.Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis. Clin. Drug Invest. 1998; 15: 13–20.
(check this in PDF content)
49
Neu H.C., Chick T.W.Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest. 1993; 104: 1393–1399.
(check this in PDF content)
50
Гучев И.А., Сафонова Е.В., Цой А.Н. Цефиксим. Клиническая эффективность при обострении нетяжелой хронической обструктивной болезни легких и влияние на развитие рецидивов заболевания. Открытое, проспективное, несравнительное исследование. Лечащий врач. 2011; 1: 86–90. / Guchev I.A., Safonova E.V., Tsoy A.N. Cefixime. Clinical efficacy in moderate chronic obstructive pulmonary disease exacerbation and influence on recurrent exacerbations. An open prospective incomparative trial. Lechashchiy vrach. 2011; 1: 86–90 (in Russian).
(check this in PDF content)
51
Lin S.H., Kuo P.H., Hsueh P.R. et al. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology. 2007; 12: 81–87.
(check this in PDF content)
52
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. http://www.srga. org/eucastwt/MICTAB
(check this in PDF content)
53
Dagan R., Johnson C.E., McLinn S. et al. Bacteriologic and clinical efficacy of amoxicillin / clavulanate vs azithromycin in acute otitis media. Pediatr. Infect. Dis. J. 2000; 19: 95–104.
(check this in PDF content)
54
Dagan R., Leibovitz E., Fliss D.M. et al.Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob. Agents Chemother. 2000; 44: 43–50.
(check this in PDF content)
55
Dagan R., Leibovitz E.Bacterial eradication in the treatment of otitis media. Lancet Infect. Dis. 2002; 2: 593–604.
(check this in PDF content)
56
Niederman M.S., Anzueto A., Sethi S. et al.Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir. Med. 2006; 100: 1781–1790.
(check this in PDF content)
57
Canut A., Martin'Herrero J.E., Labora A., Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 2007; 60: 605–612.
(check this in PDF content)
58
Ruiz'Gonzalez A., Gimenez A., Gomez'Arbones X. et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology. 2007; 12: 117–121.
(check this in PDF content)
59
Llor C., Naberan K., Cots J.M. et al.Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch. Bronconeumol. 2006; 42: 175–182.
(check this in PDF content)
60
Treyaprasert W., Schmidt S., Rand K.H. et al.Pharmacokinetic / pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int. J. Antimicrob. Agents. 2007; 29: 263–270.
(check this in PDF content)
61
Harrison C.J., Woods C., Stout G. et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J. Antimicrob. Chemother. 2009; 63 (3): 511–519.
(check this in PDF content)
62
Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.
(check this in PDF content)
63
Lieberthal A.S., Carroll A.E., Chonmaitree T. et al.The diagnosis and management of acute otitis media. Pediatrics. 2013; 131: e964–e999.
(check this in PDF content)
64
Chow A.W., Benninger M.S., Brook I. et al.IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin. Infect. Dis. 2012; 54: e72–e112.
(check this in PDF content)
65
Сидоренко С.В., Грудинина С.А., Филимонова О.Ю. и др. Резистентность к макролидам и линкозамидам среди Streptococcus pneumoniae и Streptococcus pyogenes в Российской Федерации. Клиническая фармакология и терапия. 2008; 17: 1–5. / Sidorenko S.V., Grudinina S.A., Filimonova O.Yu. et al.Antibacterial resistance of Streptococcus pneumoniae and Streptococcus pyogenes to macrolides and lincosamides in Russian Federation. Klinicheskaya farmakologiya i terapiya. 2008; 17: 1–5 (in Russian).
(check this in PDF content)
66
Mayanskiy N., Alyabieva N., Ponomarenko O. et al. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int. J. Infect. Dis. 2014; 20: 58–62.
(check this in PDF content)
67
Яковлев С.В., Сидоренко С.В., Рафальский В.В., Спи' чак Т.В.,ред. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике: Российские практические рекомендации. М.: Издательство "Престо"; 2014. / Yakovlev S.V., Sido' renko S.V., Rafal'skiy V.V., Spichak T.V., eds. Strategy of Rational Outpatient Antibacterial Therapy: Russian Practical Handbook. [Strategiya i taktika ratsional'nogo primeneniya antimikrobnykh sredstv v ambulatornoy praktike: Rossiyskie prakticheskie rekomendatsii[. Moscow: Izdatel'stvo "Presto"; 2014 (in Russian).
(check this in PDF content)
68
Гучев И.А., Козлов Р.С.Безопасность и эффективность различных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80. / Guchev I.A., Kozlov R.S.Pul'monologiya 2008; 2: 73–80 (in Russian).
(check this in PDF content)
69
Quintiliani R.Cefixime in the treatment of patients with lower respiratory tract in-fections: results of US clinical trials. Clin. Ther. 1996; 18 (3): 373–390; discuss. 372. Информация об авторах Казанцев Виктор Александрович – д. м. н., профессор, кафедра тера-
(check this in PDF content)